Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study
In another phase 1b human study conducted in the USA (ClinicalTrials.gov, NCT04143802), LY3437943 was compared with a placebo and 1.5 mg dulaglutide in patients with T2DM, demonstrating a dose-dependent body weight reduction in the LY3437943 group (68)
Huangfu, L., Li, R., Huang, Y
Cryo-electron microscopy studies (Li et al., 2024, Cell Discovery) revealed the peptide adopts a single continuous helix achieving balanced activation through conserved interactions and receptor-specific transmembrane domain contacts
Fakhrai-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, et al
Heres the catch: GLP-1 supplements are like Ozempic in the way that peewee football is like the NFL